Context: Others have argued that excessive regulation suppresses therapeutic innovation, and that the current cost of regulator-required clinical trials prevents the full exploitation of new genetic and biological knowledge for the treatment of human disease. A 2012 report by the President's Council of Advisors on Science and Technology made several key recommendations to reduce regulatory burdens to new drug development, including 1) expanding the FDA's use of accelerated approval processes, 2) creating an expedited approval pathway for drugs intended for use in narrowly defined populations, and 3) undertaking pilot projects designed to evaluate the feasibility of a new, adaptive drug approval process.

Question: Who put out a report in 2012?
Answer: President's Council of Advisors on Science and Technology

Question: What has been argued restricted innovation?
Answer: excessive regulation

Question: What was a recommendations brought about from the report?
Answer: expanding the FDA's use of accelerated approval processes

Question: What is one thing excessive regulations causes?
Answer: therapeutic innovation

Question: What can be used to evaluate new approval processes?
Answer: pilot projects

Question: What is excessive drug regulation said to suppress?
Answer: therapeutic innovation

Question: In what year was a report made to reduce the burdens of drug development?
Answer: 2012

Question: What was argued to be holding back new knowledge for treating diseases?
Answer: current cost of regulator-required clinical trials

Question: Who put out a report in 2011?
Answer: Unanswerable

Question: What has been argued restricted population?
Answer: Unanswerable

Question: What was a recommendation brought about from human disease?
Answer: Unanswerable

Question: What is one thing excessive development causes?
Answer: Unanswerable

Question: What can be used to evaluate new human diseases?
Answer: Unanswerable